Literature DB >> 26874936

The wide spectrum of cerebrotendinous xanthomatosis: Case report of a rare but treatable disease.

Francesca Rosafio1, Francesco Cavallieri1, Pietro Guaraldi2, Franco Taroni3, Paolo Frigio Nichelli1, Jessica Mandrioli4.   

Abstract

Cerebrotendinous xanthomatosis (CTX) is an autosomal-recessive disorder of lipid storage caused by mutations in the CYP27A1 gene, coding for a sterol 27-hydroxylase, leading to increased deposition of cholesterol in multiple tissues. CTX is characterized by the association of early non-neurological manifestations and adult-onset neurological dysfunctions (spastic ataxia, dementia, psychiatric disorders, peripheral neuropathy). Early and long-term treatment with chenodeoxycholic acid (CDCA) can slow down neurological symptoms progression, but diagnosis usually has a delay of several years. We report two Italian siblings having quite different phenotypes associated to a G-to-A transition in the c-1263 terminal causing a splicing alteration. This mutation has not been described before in Italy, and has been reported once in Japan. This case widens the clinical and genetic spectrum of Cerebrotendinous Xantomatosis in Italy and would like to suggest the importance of genetic testing in patients with autosomal recessive spastic paraparesis associated with typical non-neurological symptoms.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CYP27A1 gene; Cerebrotendinous xanthomatosis; Chenodeoxycholic acid; Cholesterol and cholestanol deposition; Spinocerebellar ataxia

Mesh:

Substances:

Year:  2016        PMID: 26874936     DOI: 10.1016/j.clineuro.2016.01.032

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  1 in total

Review 1.  Epidemiology, diagnosis, and treatment of cerebrotendinous xanthomatosis (CTX).

Authors:  Gerald Salen; Robert D Steiner
Journal:  J Inherit Metab Dis       Date:  2017-10-04       Impact factor: 4.982

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.